10-Q: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

SELLAS Life Sciences Group reports its financial results for the first quarter of 2025, highlighting progress in its clinical trials and recent financial activities.

Summary

• SELLAS Life Sciences Group, Inc. reported a net loss of $5.8 million for the three months ended March 31, 2025, compared to a net loss of $9.6 million for the same period in 2024.
• Research and development expenses decreased to $3.2 million from $5.1 million year-over-year, primarily due to the completion of enrollment in the REGAL study.
• General and administrative expenses decreased to $2.9 million from $4.5 million year-over-year, mainly due to lower personnel-related expenses.
• The company's cash and cash equivalents increased to $28.4 million as of March 31, 2025, compared to $13.9 million at the beginning of the period, primarily due to proceeds from a registered direct offering.
• SELLAS is conducting a Phase 3 clinical trial (REGAL study) for galinpepimut-S (GPS) in acute myeloid leukemia (AML) and a Phase 2a clinical trial for SLS009 in AML patients who failed venetoclax-based therapies.
• An interim analysis of the REGAL study recommended continuation without modifications, with the final analysis expected this year.
• Positive data was announced from the Phase 2a trial of SLS009 in r/r AML, with a median overall survival of 8.8 months in Cohort 3 patients.
• The company is pursuing discussions with pharmaceutical companies for licensing and co-development rights to its product candidates.
• SELLAS expects its cash and cash equivalents will not be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements and will require additional funding.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company is still operating at a loss, there's improvement in financial performance, positive clinical trial data, and successful fundraising. However, the need for additional funding and ongoing arbitration introduce uncertainty.

Positives

• The net loss decreased from $9.6 million in Q1 2024 to $5.8 million in Q1 2025.
• Cash and cash equivalents increased significantly due to a registered direct offering.
• The REGAL study is proceeding as planned, with a positive recommendation from the IDMC.
• SLS009 shows promising results in the Phase 2a trial for r/r AML, particularly in patients with myelodysplasia-related molecular mutations.
• GenFleet's study of SLS009 in combination with Brukinsa showed a high overall response rate in r/r DLBCL.
• The company received Rare Pediatric Disease designations from the FDA for both GPS and SLS009.

Negatives

• The company continues to incur net losses and negative cash flows from operations.
• The company expects its cash and cash equivalents will not be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements and will require additional funding.
• There is ongoing arbitration with 3D Medicines regarding milestone payments.
• The final analysis of the REGAL study is event-driven and the timing is uncertain.

Risks

• The company's future operations are dependent on securing additional financing.
• The successful development and commercialization of product candidates are subject to numerous risks and uncertainties.
• The outcome of the arbitration proceeding with 3D Medicines is uncertain.
• The company may face challenges in enrolling patients in clinical trials.
• Regulatory approvals for product candidates are not guaranteed.
• The company faces competition from other biotechnology and pharmaceutical companies.

Future Outlook

The company expects research and development expenses to increase as it continues to advance the development of GPS and SLS009 and will require substantial additional financing to commercially develop any current or future product candidates.

Management Comments

• Management continues to evaluate different strategies to obtain the required funding for future operations.
• Management is pursuing discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to the Company's product candidates.

Industry Context

SELLAS is operating in the competitive biopharmaceutical industry, focusing on novel cancer therapeutics. The company's lead product candidate, GPS, targets the WT1 protein, which is present in various tumor types, positioning it within the immuno-oncology space. SLS009, a CDK9 inhibitor, addresses hematologic and solid cancers, aligning with the industry's focus on targeted therapies. The company's partnerships and collaborations, such as with 3D Medicines and GenFleet, reflect a common strategy in the industry to expand market reach and accelerate drug development.

Comparison to Industry Standards

• SELLAS's focus on immunotherapies and targeted therapies aligns with current industry trends, as companies like Bristol Myers Squibb (Opdivo), Merck (Keytruda), and Novartis (Kymriah) have seen success in these areas.
• The Phase 3 REGAL study for GPS in AML is comparable to other late-stage clinical trials in the hematologic cancer space, such as those conducted by Agios Pharmaceuticals (Tibsovo) and Jazz Pharmaceuticals (Vyxeos).
• The development of SLS009 as a CDK9 inhibitor places SELLAS in competition with other companies developing similar therapies, such as those being developed by Constellation Pharmaceuticals (CPI-0610) and others.
• The company's licensing agreements with 3D Medicines and GenFleet are similar to other partnerships in the biopharmaceutical industry, such as those between Roche and Blueprint Medicines, to expand market access and accelerate drug development.

Legal Proceedings

• The company is involved in a binding arbitration proceeding against 3D Medicines regarding milestone payments and development efforts.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial progress impact shareholder value.
• Employees: The company's ability to secure funding and advance its programs affects job security and opportunities.
• Patients: The development of new cancer therapies has the potential to improve treatment options and outcomes for patients.
• Partners: The company's collaborations with 3D Medicines and GenFleet impact the development and commercialization of its product candidates.

Next Steps

• Continue the Phase 3 REGAL study for GPS, with the final analysis expected this year.
• Advance the Phase 2a clinical trial for SLS009 in r/r AML.
• Pursue discussions with pharmaceutical companies for licensing and co-development rights.
• Seek additional financing to fund operations and development programs.

Key Dates

Keywords

SELLAS Life Sciences, Galinpepimut-S, SLS009, AML, Clinical Trial, Financial Results, REGAL Study, CDK9 Inhibitor, Rare Pediatric Disease, 3D Medicines, GenFleet